FORMULATION ARTICLES
-
![Virology, infectious diseases, virus diagnostics, virus research, biotechnology-GettyImages-2219621039]( "RNA Platforms: What Transfers And What Breaks")
RNA Platforms: What Transfers And What BreaksA practical framework for distinguishing reusable RNA platform knowledge from biology-specific unknowns as therapeutics expand into new tissues and indications.
-
![vaccine, vaccination, virus dna doubts questions-GettyImages-1308261360]( "The Hidden Language Of RNA: How lncRNA-Splicing Networks Are Redefining The Future Of Therapeutics")
The Hidden Language Of RNA: How lncRNA-Splicing Networks Are Redefining The Future Of TherapeuticsLong non-coding RNAs and splicing networks are emerging as master regulators of cellular identity, opening new therapeutic opportunities beyond proteins.
-
![Ribosome as part of an biological cell constructing mRNA molecule-GettyImages-1352440312]( "RNA-Binding Proteins As Architects Of Post-Transcriptional Control In Disease Biology")
RNA-Binding Proteins As Architects Of Post-Transcriptional Control In Disease BiologyRNA-binding proteins orchestrate splicing, stability, localization, and translation, emerging as powerful regulators and therapeutic targets in disease.
-
![Emergency medicine-GettyImages-2055655561]( "Targeting The Uncharted Heart: Why The Next Era Of siRNA Belongs In Cardiology")
Targeting The Uncharted Heart: Why The Next Era Of siRNA Belongs In CardiologyDuring our conversation, Gallagher walked me through what’s keeping her up at night as she leads the company and its first siRNA candidate toward an IND, elaborating on the role RNA can play in cardiomyopathies and identifying the unique challenges of developing RNA medicines today.
-
![molecular scissors, manipulation of molecular biology, RNA molecule-GettyImages-2213997299]( "Structure-Guided siRNA Design: How Chemistry, Context, And Constraint Are Shaping The Next Phase Of RNAi Therapeutics")
Structure-Guided siRNA Design: How Chemistry, Context, And Constraint Are Shaping The Next Phase Of RNAi TherapeuticsAs siRNA design matures, the next breakthroughs will depend on balancing chemical optimization, delivery challenges, and expanding beyond established design rules.
-
![GettyImages-1487902757]( "Following The Data To The Heart: Atrium's Quest For Next-Gen Targeted RNA Delivery")
Following The Data To The Heart: Atrium's Quest For Next-Gen Targeted RNA DeliveryIn this two-part series, Gallagher shares more about her goals for Atrium following its spin-out from Novartis, articulating what it looks like and means to “pave a path” to greater patient access in rare cardiomyopathies. Here in part one, we start with a look into the formation of Atrium, sharing the “why” behind the company’s formation and what’s next for the company’s targeted delivery platform.
FORMULATION VIDEOS
NanoVation Therapeutics’ Dominik Witzigmann and Stealth Co’s John Zuris walk us through the challenges active delivery strategies pose, particularly as it relates to receptor selection, and the emerging technologies/tools that can help us achieve greater delivery specificity to the target cell type.
Discover key strategies for controlling LNP formulation and upscaling. Explore the science behind lipid nanoparticles, critical parameters, and achieving effective turbulent mixing for optimal outcomes.
Explore how lipid nanoparticles are revolutionizing non-viral gene editing with scalable, efficient delivery for both ex vivo and in vivo applications, which features new CRISPR-LNP data in T cells.
Unlock seamless transition from lab-scale nanoparticle research to commercial production. Learn how scalable turbulent-jet mixing ensures precise, uniform, and reproducible formulation results.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![Medical scientists analyzing research-GettyImages-1413600685]( "Developing A Comprehensive Regulatory Approach For LNP Drugs")
The path to regulatory approval for LNPs demands carefully considered strategies. By adopting proactive and strategic approaches, developers can overcome regulatory hurdles on the path to approval.
-
![Outsourcing RNA Feature Image]( "Outsourcing RNA-LNP Production: A Key To Competitive Success")
Manufacturing RNA-containing LNPs demands specialized expertise. Explore some of the challenges of RNA-LNP drug manufacturing and the advantages of outsourcing RNA-LNP formulations.
-
![GettyImages-1418152314]( "Unpacking The Importance Of Lipid Nanoparticle Production Platforms")
Batch processing platforms for LNPs lack efficiency, appropriate controls, and yield optimization. Continuous manufacturing platforms may address some of those issues.
-
![GettyImages-597935610 cell and gene]( "Delivering The Promise Of Gene Therapy")
Gene therapies rely on efficient, precise methods of delivering genetic material. Examine how combining polymeric nanoparticles with CRISPR therapies is increasing the potential for improved treatment.
-
![RNA abbreviation of ribonucleic acid-GettyImages-1453953422]( "Exploring Osmolality As A CQA Within RNA Therapeutics")
Discover how osmolality can be applied throughout the bioprocessing workflow for RNA, and recognize the importance of this sensitive measurement, from formulation optimization to cryopreservation techniques.
-
![Cell Gene Technology]( "Where Can Novel Non-Viral Polymeric Delivery Agents Take Us?")
Explore ongoing work to harness different types of HDR templates in order to build cutting-edge systems with the potential to enable point-of-care cell and gene therapy manufacture.
-
![GettyImages-1264101698-lab-research-scientist]( "Lipid Nanoparticle Library For Non-Viral Delivery Of mRNA And saRNA Towards Vaccine And Cell & Gene Therapy Applications")
Explore this proprietary ionizable lipid library which has shown promising potency towards various applications involving cell therapy, protein replacement therapy and RNA-based Vaccines.
